Clovis Oncology, Inc. (USA) recently announced that the first clinical site for the Phase 1/2 LuMIERE study of FAP-2286, its novel peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein (FAP), is now open at the O’Neal Comprehensive Cancer Center at The University of Alabama at Birmingham (UAB).

The O'Neal Comprehensive Cancer Center at UAB is among the leading cancer research institutions of the USA and one of only 51 comprehensive cancer centers designated by the National Cancer Institute.

The Phase 1 portion of the LuMIERE study will evaluate the safety of the FAP-targeting investigational therapeutic agent and identify the recommended Phase 2 dose and schedule of lutetium-177 labeled FAP-2286 (¹⁷⁷Lu-FAP-2286). FAP-2286 labeled with gallium-68 (⁶⁸Ga-FAP-2286) will be utilized as an investigational imaging agent to identify patients with FAP-positive tumors appropriate for treatment with the therapeutic agent. Once the Phase 2 dose is determined, Phase 2 expansion cohorts are planned in multiple tumor types.

To read more please visit:

https://ir.clovisoncology.com/investors-and-news/news-releases/press-release-details/2021/Clovis-Oncology-Announces-LuMIERE-Clinical-Trial-Evaluating-Novel-Peptide-Targeted-Radionuclide-Therapy-FAP-2286-Now-Open-for-Enrollment/default.aspx

Source: CLOVIS Oncology